Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review

Jan M. Leerink*, Simone J. Verkleij, Elizabeth A. M. Feijen, Annelies M. C. Mavinkurve-Groothuis, Milanthy S. Pourier, Kaisa Ylanen, Wim J. E. Tissing, Marloes Louwerens, Marry M. van den Heuvel, Eline van Dulmen-den Broeder, Andrica C. H. de Vries, Cecile M. Ronckers, Heleen J. H. van der Pal, Livia Kapusta, Jacqueline Loonen, Louise Bellersen, Yigal M. Pinto, Leontien C. M. Kremer, Wouter E. M. Kok

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)

Abstract

Objective To systematically review the literature and assess the diagnostic value of biomarkers in detection of late-onset left ventricular (LV) dysfunction in childhood cancer survivors (CCS) treated with anthracyclines. Methods We systematically searched the literature for studies that evaluated the use of biomarkers for detection of LV dysfunction in CCS treated with anthracyclines more than 1 year since childhood cancer diagnosis. LV dysfunction definitions were accepted as an ejection fraction

Original languageEnglish
Pages (from-to)210-216
Number of pages7
JournalHeart
Volume105
Issue number3
DOIs
Publication statusPublished - 15-Jan-2019

Keywords

  • systemic review
  • heart failure
  • cardiac imaging and diagnostics
  • LONG-TERM SURVIVORS
  • NATRIURETIC PEPTIDE
  • HEART-FAILURE
  • TROPONIN-T
  • CARDIAC DYSFUNCTION
  • STATISTICS NOTES
  • HEALTH OUTCOMES
  • FOLLOW-UP
  • HIGH-RISK
  • GUIDELINE

Cite this